Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians

Por YLIKORKALA, O., MIKKOLA, T.
Publicado no Reprod Med Biol (2005)

Thromboxane A2 in pregnancy and puerperium.

Por Ylikorkala, O, Viinikka, L
Publicado em 1980

Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.

Por Venesmaa, P., Ylikorkala, O.
Publicado em 1991

Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum.

Por Viinikka, L., Ylikorkala, O.
Publicado em 1981

Concentrations of zinc and copper in pregnant problem drinkers and their newborn infants.

Por Halmesmaki, E, Ylikorkala, O, Alfthan, G
Publicado em 1985

The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.

Por Viinikka, L, Toivanen, J, Ylikorkala, O
Publicado em 1982

Prostacyclin and thromboxane in diabetes.

Por Ylikorkala, O, Kaila, J, Viinikka, L
Publicado em 1981

Raised serum human chorionic gonadotrophin concentrations in hyperemesis gravidarum.

Por Kauppila, A, Huhtaniemi, I, Ylikorkala, O
Publicado em 1979

Plasma prostacyclin from birth to adolescence.

Por Kääpä, P, Viinikka, L, Ylikorkala, O
Publicado em 1982

Fetal and neonatal prostacyclin and thromboxane in relation to mode of delivery.

Por Ylikorkala, O, Pohjavuori, M, Rovamo, L
Publicado em 1986

Sulpiride improves inadequate lactation.

Por Ylikorkala, O, Kauppila, A, Kivinen, S, Viinikka, L
Publicado em 1982

Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment.

Por Aitokallio-Tallberg, A., Viinikka, L., Ylikorkala, O.
Publicado em 1989

Neonatal respiratory distress caused by aspiration of a vaginal tablet containing prostaglandin.

Por Andersson, S, Paetau, R, Hallman, M, Vapaatalo, H, Ylikorkala, O
Publicado em 1987

Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer.

Por Aitokallio-Tallberg, A., Lehtovirta, P., Vartiainen, J., Ylikorkala, O.
Publicado em 1995

Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate.

Por Aitokallio-Tallberg, A., Kärkkäinen, J., Pantzar, P., Wahlström, T., Ylikorkala, O.
Publicado em 1985

Urinary epidermal growth factor concentrations in various human malignancies.

Por Mattila, A. L., Saario, I., Viinikka, L., Ylikorkala, O., Perheentupa, J.
Publicado em 1988

Human vascular endothelial cells produce TNF-α after stimulation with proinflammatory cytokines

Por Ranta, V, Orpana, A, Carpén, O, Turpeinen, U, Ylikorkala , O, Viinikka, L
Publicado em 1999

Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.

Por Venesmaa, P., Lehtovirta, P., Stenman, U. H., Leminen, A., Forss, M., Ylikorkala, O.
Publicado em 1994

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women

Por Marttunen, M B, Cacciatore, B, Hietanen, P, Pyrhönen, S, Tiitinen, A, Wahlström, T, Ylikorkala, O
Publicado em 2001

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

Por Goldstein, S. R., Bachmann, G. A., Koninckx, P. R., Lin, V. H., Portman, D. J., Ylikorkala, O.
Publicado em 2014